Oragenics Receives Unqualified Audit Opinion with Going Concern Paragraph
Oragenics’ audited consolidated financial statements for the year ended December 31, 2025 included an unqualified audit opinion with an explanatory going concern paragraph flagged in footnote 1 of its Form 10-K filed March 16, 2026. The company confirmed no amendments to its financial statements or annual report despite the NYSE American Rule 610(b) requirement.
1. Audit Opinion and Going Concern Disclosure
The independent auditor issued an unqualified opinion on Oragenics’ consolidated financial statements for the fiscal year ended December 31, 2025, while including an explanatory paragraph regarding the company’s ability to continue as a going concern. This disclosure highlights uncertainties around the firm’s cash runway relative to advancing its clinical programs.
2. Financial Reporting and Filing Details
The going concern paragraph appears in footnote 1 of the Form 10-K filed March 16, 2026, with no subsequent amendments to the annual report or audited statements. The announcement fulfills NYSE American LLC Company Guide Section 610(b) requirements without altering previously disclosed financial figures.
3. Operational Implications
The going concern warning may raise questions about Oragenics’ near-term financing needs to support its Phase IIa program for ONP-002 and broader CNS pipeline development. Securing additional capital or strategic partnerships will be critical to address the auditor’s concerns and fund ongoing operations.